China Biotech Services Holdings Ltd (8037) fair value: what the stock is really worth
As of Oct 7, 2026: fair value of China Biotech Services Holdings Ltd HK$0.31, price HK$0.54, upside -42.1%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range HK$0.2600 – HK$2.28 · fair‑value band HK$0.2400 – HK$0.3900 · the HK$0.5350 price screens above the HK$0.3100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow China Biotech Services Holdings in your weekly email
Every Wednesday you see whether China Biotech Services Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People's Republic of China and Hong Kong. The company operates through Medical and Health Related Services, Immunotherapy, Pharmaceutical Products, Insurance Brokerage, BNCT, and Others segments.
Show more
China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People's Republic of China and Hong Kong. The company operates through Medical and Health Related Services, Immunotherapy, Pharmaceutical Products, Insurance Brokerage, BNCT, and Others segments. It also engages in the provision of tumor immune cell therapy and health management services; sale and distribution of health related and pharmaceutical products; insurance brokerage services; provision of boron neutron capture therapy treatment services, as well as provision of logistic services. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017. China Biotech Services Holdings Limited was founded in 1996 and is headquartered in Causeway Bay, Hong Kong.
Stock analysis
China Biotech Services Holdings Ltd (8037) currently trades at HK$0.5350, while our model-based Fair Value estimate is HK$0.3100, 42.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 87/100, which puts the evidence level at low.
Scenario range: HK$0.2400 (bear) to HK$0.3900 (bull), the price of HK$0.5350 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
China Biotech Services Holdings Ltd reported revenue of HK$73.5M in FY2025 versus HK$624M in FY2021, a compound −41.4%/yr. Reported net income was −HK$68.8M in FY2025.
Key figures
Market cap HK$522M (≈ $66.5M) · P/S ratio 5.67 · EPS (TTM) HK$−0.0300 · Net margin −93.6% · Return on equity −40.6% · Return on assets (EBIT) 5.5% · Operating margin −138% · Revenue (TTM) HK$73.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −42%, 8037 screens richer than that median.
Fair Value models
Bear HK$0.2400Fair Value HK$0.3100Bull HK$0.3900
Price HK$0.5350 · Upside -42.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−65.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−35.4%
Start year 2020 (pandemic)
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
’13
’14
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
29.5% (2020) → −103.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare China Biotech Services Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−42.1% · Below median
Profitability
Return on assets−7.5% · Bottom 25%
Net margin (TTM)−93.6% · Bottom 25%
Operating margin (TTM)−138.5% · Bottom 25%
Growth and dividend
Revenue growth−9.0% · Bottom 25%
Balance sheet
Debt / equity1.00× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B0.35× · Cheapest 25%
P/S (TTM)0.91× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 22
PAST (return on equity)0· sector 13
HEALTH (low debt)50· sector 93
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is China Biotech Services Holdings Ltd (8037) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of HK$0.3100 versus a price of HK$0.5350, about −42% upside (overvalued).
What is the fair value of 8037?
Our model-based fair value for China Biotech Services Holdings Ltd is HK$0.3100 (as of Oct 3, 2026), built from audited fundamentals. The current price: HK$0.5350.
What is the quality score of 8037?
China Biotech Services Holdings Ltd has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for China Biotech Services Holdings Ltd (8037)?
Our model-based price target is the fair value of HK$0.3100 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario HK$0.2400, optimistic scenario HK$0.3900. It is a calculation from audited fundamentals, not an analyst target.
What is the China Biotech Services Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$0.3100, about −42% upside versus a price of HK$0.5350 (overvalued). Cautious scenario HK$0.2400, optimistic scenario HK$0.3900. The calculation is refreshed regularly with new filings.
What is the revenue of China Biotech Services Holdings Ltd (8037)?
China Biotech Services Holdings Ltd reported trailing-twelve-month revenue of about HK$73.5M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of China Biotech Services Holdings Ltd (8037)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Biotech Services Holdings Ltd it is HK$0.3100 per share (as of Oct 3, 2026), against a price of HK$0.5350. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is China Biotech Services Holdings Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 8037 trades above its calculated fair value: price HK$0.5350, fair value HK$0.3100, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8037?
No. The price is what the market pays today (HK$0.5350); the fair value is what the company's own numbers justify (HK$0.3100). For China Biotech Services Holdings Ltd the two are HK$0.2250 per share apart. That gap is exactly why we show both numbers side by side.
How much is China Biotech Services Holdings Ltd worth?
The market values China Biotech Services Holdings Ltd at about HK$522M (market capitalisation, as of Oct 3, 2026). Per share that is HK$0.5350; our models calculate a fair value of HK$0.3100 per share.
What do the bullish and bearish scenarios say about 8037?
Our models span a range for China Biotech Services Holdings Ltd: cautious scenario HK$0.2400, base HK$0.3100, optimistic HK$0.3900 per share (as of Oct 3, 2026, price HK$0.5350). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of China Biotech Services Holdings Ltd (8037)?
Balance-sheet figures for China Biotech Services Holdings Ltd (as of Oct 3, 2026): return on equity −40.6%, debt of 1.00 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 8037 from its 52-week high?
China Biotech Services Holdings Ltd trades at HK$0.5350, about 48% below its 52-week high of HK$1.03 and 26% above the low of HK$0.4250 (as of Oct 7, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.3100 is for.
Which stocks are comparable to China Biotech Services Holdings Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is China Biotech Services Holdings Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price HK$0.5350, calculated fair value HK$0.3100 (−42%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8037 calculated?
We run China Biotech Services Holdings Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.3100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.3 % above its aggregate fair value. China Biotech Services Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of China Biotech Services Holdings Ltd (8037)?
The closing price on Oct 7, 2026 was HK$0.5350. Our model-based fair value is HK$0.3100, about −42% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with China Biotech Services Holdings Ltd right now?
The price sits above even our optimistic bull case (HK$0.3900). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of China Biotech Services Holdings Ltd
How large is the market capitalisation of China Biotech Services Holdings Ltd (8037)?
The market capitalisation of China Biotech Services Holdings Ltd is HK$522M (≈ $66.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of China Biotech Services Holdings Ltd (8037)?
The price-to-sales ratio of China Biotech Services Holdings Ltd is 5.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of China Biotech Services Holdings Ltd (8037)?
Earnings per share at China Biotech Services Holdings Ltd are HK$−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of China Biotech Services Holdings Ltd (8037)?
The net margin of China Biotech Services Holdings Ltd is −93.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of China Biotech Services Holdings Ltd (8037)?
The return on equity (ROE) of China Biotech Services Holdings Ltd is −40.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of China Biotech Services Holdings Ltd (8037)?
On an EBIT basis the return on assets of China Biotech Services Holdings Ltd is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of China Biotech Services Holdings Ltd (8037)?
The operating margin of China Biotech Services Holdings Ltd is −138% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at China Biotech Services Holdings Ltd (8037)?
Revenue at China Biotech Services Holdings Ltd is growing −9.0% versus a year earlier (3y avg −65.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at China Biotech Services Holdings Ltd (8037)?
Earnings per share at China Biotech Services Holdings Ltd are growing +735% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does China Biotech Services Holdings Ltd (8037) generate?
The free cash flow of China Biotech Services Holdings Ltd is −HK$197M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does China Biotech Services Holdings Ltd (8037) carry?
The net debt of China Biotech Services Holdings Ltd is HK$383M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch China Biotech Services Holdings Ltd in the live analysis
One click puts China Biotech Services Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
